Machine learning-based decision support model for selecting intra-arterial therapies for unresectable hepatocellular carcinoma: A national real-world evidence-based study.

Journal: British journal of cancer
PMID: 38971951

Abstract

IMPORTANCE: Intra-arterial therapies(IATs) are promising options for unresectable hepatocellular carcinoma(HCC). Stratifying the prognostic risk before administering IAT is important for clinical decision-making and for designing future clinical trials.

Authors

  • Chao An
    Department of Minimal invasive intervention, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Ran Wei
  • Wendao Liu
    Department of Interventional Therapy, Guangdong Provincial Hospital of Chinese, Medicine and Guangdong Provincial Academy of Chinese Medical Sciences, No. 111 Dade Road, Guangzhou, 510080, Guangdong, People's Republic of China. Liu_wendao_2023@163.com.
  • Yan Fu
    School of Chemical Engineering and Technology, Tianjin University, Tianjin, 300350, PR China. Electronic address: fuyan@tju.edu.cn.
  • Xiaolong Gong
    Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Interventional Radiology Department, No. 440, Jiyan Road, Jinan, Shandong Province Jinan, Shandong, China.
  • Chengzhi Li
    Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, 510060, People's Republic of China. lichengzhi@jnu.edu.cn.
  • Wang Yao
    Department of Reproductive Medicine, The First Affiliated Hospital, Jinan University Guangzhou 510000, Guangdong, China.
  • Mengxuan Zuo
    Department of Minimal Invasive Intervention, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651, Dongfeng East Road, Guangzhou, 510060, People's Republic of China.
  • Wang Li
    School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, China.
  • Yansheng Li
    DHC Mediway Technology Co., Ltd., Beijing, China.
  • Fatian Wu
    DHC Mediway Technology Co., Ltd, Beijing, China.
  • Kejia Liu
    DHC Mediway Technology Co., Ltd., Beijing, China.
  • Dong Yan
    School of Civil and Hydraulic Engineering, Huazhong University of Science and Technology, Wuhan, 430074, China.
  • Peihong Wu
    Department of Medical Imaging and Image-guided Therapy, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
  • Jianjun Han
    Department of Colorectal Cancer Surgery, Shandong Cancer Hospital and Institute, 440 Jiyan Road, Jinan, 250117, China. handoctor@139.com.

Keywords

External Resources

Popular Topics
Recent Journals